| Home | E-Submission | Sitemap | Contact Us
JPTM > Ahead-of Print

doi: https://doi.org/10.4132/jptm.2017.04.10    [Epub ahead of print]
Molecular Testing of Lung Cancers
Hyo Sup Shim1, Yoon-La Choi2, Lucia Kim3, Sunhee Chang4, Wan-Seop Kim5, Mee Sook Roh6, Tae-Jung Kim7, Seung Yeon Ha8, Jin-Haeng Chung9, Se Jin Jang10, Geon Kook Lee11, The Korean Cardiopulmonary Pathology Study Group, The Korean Molecular Pathology Study Group
1Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
2Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3Department of Pathology, Inha University School of Medicine, Incheon, Korea
4Department of Pathology, Inje University Ilsan Paik Hospital, Inje University, Goyang, Korea
5Department of Pathology, Konkuk University School of Medicine, Seoul, Korea
6Department of Pathology, Dong-A University College of Medicine, Busan, Korea
7Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea
8Department of Pathology, Gachon University Gil Medical Center, Incheon, Korea
9Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea
10Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
11Department of Pathology, National Cancer Center, Goyang, Korea
Corresponding Author: Geon Kook Lee ,Tel: +82-31-920-1746, Fax: +82-31-920-1369, Email: gklee@ncc.re.kr
Received: April 3, 2017;  Accepted: April 9, 2017.  Published online: April 21, 2017.
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.
Key Words: Lung neoplasms; Molecular testing; Guideline; Precision medicine
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Supplement  Supplement
Related articles
Molecular Testing for Gastrointestinal Cancer  2017 March;51(2)
Expression of p63 in Lung Cancer.  2003 April;37(2)